NCT01579760View on ClinicalTrials.gov

Intravitreal Aflibercept Injection for Radiation Retinopathy

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

January 31, 2019

Study Completion Date

March 27, 2019

Conditions
Radiation RetinopathyMacular Edema
Interventions
DRUG

Aflibercept every 2 months

2.0 mg aflibercept intravitreal injections once per month for the first 3 months (M0, M1, M2), then every 2 months (M4, M6, M8, M10)

DRUG

Aflibercept monthly

2.0mg aflibercept intravitreal injections every month (M0-11)

Trial Locations (2)

63110

Washington University School of Medicine, St Louis

77030

Retina Consultants of Houston, Houston

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT01579760 - Intravitreal Aflibercept Injection for Radiation Retinopathy | Biotech Hunter | Biotech Hunter